3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
177
Lung Neoplasms
59
Neoplasms
24
Neoplasm Metastasis
17
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Mesothelioma, Malignant
12
Carcinoma
11
Colorectal Neoplasms
10
Mesothelioma
9
Meningeal Carcinomatosis
8
Melanoma
7
Brain Neoplasms
7
Pancreatic Neoplasms
6
Adenocarcinoma of Lung
6
Advanced Solid Tumors
5
Uterine Cervical Neoplasms
4
Ovarian Neoplasms
4
Neoplasms by Site
4
Colonic Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Rectal Neoplasms
3
Non-squamous Non-small Cell Lung Cancer
3
Neoplasms by Histologic Type
3
NSCLC
3
Lung Diseases
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Bronchogenic
3
Adenocarcinoma
3
Thoracic Neoplasms
2
Interventions
lutetium Lu 177 dotatate
20
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Specimen Handling
7
Everolimus
7
cabozantinib
6
Nivolumab
6
lenvatinib
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
surufatinib
4
amino-acid, glucose, and electrolyte solution
4
Capecitabine
4
olaparib
3
lanreotide
3
atezolizumab
3
Temozolomide
3
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Pemetrexed
×
1 year
×
Clear all
No trials found.